LIGAND PHARMACEUTICALS INCORPORATED
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $63.7M | $51.7M | $59.7M | $115.5M | $47.6M | $45.3M | $42.8M | $51.8M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $14.7M | $2.1M | $3.5M | $21.0M | $6.6M | $50.1M | $4.4M | $5.7M |
| SG&A Expense | $29.1M | $20.8M | $25.0M | $28.4M | $20.2M | $18.8M | $25.6M | $24.5M |
| Operating Income | $8.6M | $17.4M | $13.8M | $54.9M | $8.4M | $-36.2M | $-9.6M | $3.1M |
| Operating Margin | 13.5% | 33.6% | 23.2% | 47.6% | 17.7% | -79.9% | -22.5% | 6.1% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $64.3M | $-24.3M | $56.8M | $141.1M | $11.2M | $-50.2M | $-39.2M | $-6.3M |
| Income Tax Expense | $15.8M | $-10.9M | $12.0M | $23.9M | $6.4M | $-7.7M | $-8.1M | $833.0K |
| Net Income | $48.5M | $-13.3M | $44.8M | $117.3M | $4.8M | $-42.5M | $-31.1M | $-7.2M |
| Net Margin | 76.2% | -25.8% | 75.1% | 101.6% | 10.2% | -93.6% | -72.6% | -13.8% |
| EPS (Basic) | $2.42 | $-0.67 | $2.41 | $5.99 | $0.25 | $-2.21 | $-1.81 | $-0.39 |
| EPS (Diluted) | $2.22 | $-0.67 | $2.42 | $5.68 | $0.24 | $-2.21 | $-1.70 | $-0.39 |
| Shares Outstanding (Basic) | 20.1M | 19.9M | 19.3M | 19.6M | 19.3M | 19.2M | 18.3M | 18.4M |
| Shares Outstanding (Diluted) | 21.8M | 19.9M | 20.3M | 20.6M | 19.9M | 19.2M | 18.3M | 18.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |